Latest Breaking News On - Eli lilly omvoh - Page 1 : comparemela.com

As Stelara nears patent cliff, J&J fortifies Tremfya for upcoming ulcerative colitis showdown

As Stelara nears patent cliff, J&J fortifies Tremfya for upcoming ulcerative colitis showdown
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

United statesUniversity of chicagoJeff stewartJoaquin duatoJohnson tremfyaDavidt rubinEli lilly omvohEuropean medicines agencyDigestive diseaseEli lillyEuropean medicines

Pfizer s Velsipity faces stiff competition in UC market: reports

Pfizer s Velsipity faces stiff competition in UC market: reports
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

Eli lilly omvohAbbvie humiraFilippos maniatisTakeda entyvioJim hickeyEli lillyFierce pharma marketingSpherix global insightsFierce pharma

J&J lands two cancer drugs on Clarivate list of Drugs to Watch

J&J lands two cancer drugs on Clarivate list of Drugs to Watch
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

Daiichi sankyoCallidita tarpeyoRoche vabysmoEli lilly omvohClarivate analytic drugsEli lilly

FDA ends 2023 on high note for GI: Ulcerative colitis pipeline teeming with new approvals

FDA ends 2023 on high note for GI: Ulcerative colitis pipeline teeming with new approvals
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Eli lilly omvohBymonica stonehillZeposia ozanimodStates zymfentraRobert stottRedhill biopharmaEli lillyGilead sciencesTakeda pharmaceuticalsProcisedx incBristol myers squibbTakeda pharmaceutical entyvioCelltrion united statesPhathom pharmaceutical voqueznaVoquezna tripleDual pak

InDex Scraps Phase III Ulcerative Colitis Trial on Disappointing Data

After a negative review by an Independent Data Monitoring Committee, InDex Pharmaceuticals has decided to discontinue the late-stage CONCLUDE program evaluating its cobitolimod in ulcerative colitis.

Eli lilly omvohJenny sundqvistData monitoring committeeTelevant holdingsIndex pharmaceuticals onDex pharmaceuticalsIndependent data monitoring committeeInduction studyEli lillyNdex scraps phase iii ulcerative colitis trial on disappointing data